CLINICAL GUIDEI	LINE			
Subject: Anticoag	ulation Policy	Bedford Hospital NHS Trust		
TRUSTWIDE				
Reviewed by: Consultant Haematologist Lead Pharmacist for Anticoagulation		Key Reference: NPSA Patient Safety Alert No. 18 Guidelines on oral anticoagulation – British Journal of Haematology 4 th Edition		
Date of Approval:	March 2019	Review Date: March 2021		
Purpose	This policy aims to amalgamate all current Trust guidance relating to anticoagulation. To reduce the incidence of VTE and provide a consistent and coherent approach towards the use and monitoring of anticoagulant therapy, patient management and co-ordination within Bedfordshire in compliance with the NPSA safety alert, 'Actions that can make anticoagulant therapy safer', March 2007. For the purpose of this guideline 'anticoagulation' refers to warfarin, NOACs, LMWH and heparin. This policy and related policies provide guidance on the management of			
Objectives	 anticoagulation in adults only. The guidance covers the following key areas: Prescribing responsibilities for medical and non-medical prescribers: initiation, continuation, monitoring and discontinuation of anticoagulant therapy including switching between anticoagulants Competency of all staff involved with anticoagulant prescribing, administration, supply and discontinuation. Safe systems for documenting results and treatment, including effective communication on discharge Providing the patient with the appropriate information at commencement, throughout the course of treatment and on discharge from inpatient services. Providing standardised and clinically effective anticoagulation management whilst minimising the risks associated with treatment. Optimising care to patients receiving anticoagulant therapy in terms of accessibility, continuity and waiting times Ensuring complete and accurate documentation of the clinic process. 			
For Use By	All qualified medical and nursing staff prescribing / dispensing / administering parenteral, subcutaneous and oral anticoagulants			
Related Policies Any policies or guidelines that directly impact or are impacted by this Guideline	Listed within policy.	-		
Definitions Any Acronyms or Abbreviations used in Guideline	ACS-Acute Coronary SynAF-Atrial FibrillationAPS-Antiphospholipid synBSH-British Committee forCVA-Cerebral Vascular /DOAC-Direct Oral AnticoageDTI-Direct thrombin inhitionDVT-Deep Vein Thrombox	ndrome or Standards in Haematology Accident (Stroke) gulant bitor		

	500	
		- Full blood count
		- Fresh frozen plasma
		 Activated factor X
		 Gastro-oesophageal Reflux Disease
	INR	 International Normalised Ratio
	IV	- Intra-Venous
	LMWH	 Low Molecular Weight Heparin (e.g. tinzaparin)
	LFT	- Liver function tests
	LSCS	 Lower segment caesarean section
		- Myocardial Infarction
		- National Institute for Health and Care Excellence
		- Non-medical Prescriber
		 Non-Vitamin K antagonist oral anticoagulant
		 National Patient Safety Agency now National Reporting and
		Learning System (NRLS)
	OAS	Outpatient anticoagulation service
		- Oral Anticoagulation Therapy: including warfarin and NOACs
		- Out of Hours
		 Prothrombin Complex Concentrate
		 Pulmonary Embolism
		 Patient information leaflet
		Per os (orally)Point of Care
		- Peptic Ulcer Disease
		- Peripheral Vascular Disease
		- 'To Take Out' Discharge prescription
		- Time in Therapeutic Range
		- Vitamin K Antagonist e.g. warfarin
	VTE	 Venous Thromboembolism: including DVT, PE and post-
		thrombotic syndrome
		Warfarin, Oral anticoagulants, Anticoagulation, INR, NOAC,
		/H, Heparin, Tinzaparin, Beriplex, Apixaban, Edoxaban,
		n, Dabigatran, Praxbind, Idarucizumab
Status / Version	Version 1.0	
Control		'Warfarin (Use in adult inpatients)' and 'Oral anticoagulation
Previous versions of	(Vitamin K a	ntagonists) and the role of the outpatient clinic' clinical guidelines.
the Guideline should be		
stated here with former		
name if changed along with dates when they		
were approved.		

Contents

Purpose	1
Objectives	1
For Use By	1
Related Policies	1
Definitions	1
Status / Version Control	2
INTRODUCTION	5
ASSOCIATED GUIDELINES	5
1. WARFARIN GUIDANCE	6
Initiation	6
Warfarin Induction Dosage Chart for Venous Thrombosis	6
Warfarin Induction Dosage Chart for Atrial Fibrillation	7
Recommended Therapeutic INR Targets and Duration	8
Dosage Management and Monitoring	9
2. DISCHARGE OF INPATIENTS TAKING ANTICOAGULANTS	11
3. ANTICOAGULATION REFERRAL FORM	15
4. SWITCHING BETWEEN ANTICOAGULANTS	17
5. DRUG INTERACTIONS AND ADMINISTRATION IN PATIENTS WITH S DIFFICULTIES AND/OR ENTERAL FEEDING TUBES	
Significant Drug Interactions with Warfarin –Mechanism and Management	
NOAC Drug Interactions	20
Administration to patients with enteral feeding tubes or swallowing difficult	ies 21
6. MANAGEMENT OF OVER ANTICOAGULATION AND REVERSAL OF	BLEEDING 22
Warfarin	22
NOACs	22
Praxbind (Idarucizumab) Information	24
Use of Prothrombin Complex Concentrate (Beriplex) at Bedford Hospital	26
7. MANAGEMENT OF ENDOSCOPY PATIENTS ON ANTICOAGULATIO	N26
8. ANTICOAGULATION AND EPIDURAL INFUSIONS	26
9. OTHER VITAMIN K ANTAGONISTS	27
10. THROMBOPHILIA AND TESTING	27
11. TRAVEL-RELATED VENOUS THROMBOEMBOLISM	29
12. ANTICOAGULATION OUTPATIENT SERVICES IN BEDFORDSHIRE	
Bedford Warfarin Service	
Anticoagulation Clinic Service at Bedford Hospital	31
13. BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE	ADVICE 33
14. AUDIT	
15. EDUCATION AND TRAINING	
FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101	Page 3 of 41

Prescribers	34
Nursing Staff	34
Pharmacy Staff	34
16. RESPONSIBILITIES	34
Haemostasis and Thrombosis Committee	34
Prescribers	34
Nursing Staff	35
Pharmacy Staff	36
References	37
Approving Signatories	39
Consultation List	40

INTRODUCTION

Anticoagulants are high risk medications. This policy provides guidance and signposts to all Trust clinical guidance related to the prescribing, dispensing and administration of warfarin, NOACs/DOACs, tinzaparin and unfractionated heparin to ensure safe and cost-effective use of these medicines.

ASSOCIATED GUIDELINES

- Prevention of Hospital Acquired Venous Thromboembolism
- Prevention and treatment of Venous Thromboembolism in pregnancy and the puerperium
- Atrial Fibrillation in the Acute Setting (investigation and management of)
- Non Vitamin K Antagonist Oral Anticoagulants (NOACs) in Non-Valvular Atrial Fibrillation: Initiation of treatment
- Non Vitamin K Antagonist oral anticoagulants (NOACs): Management of cardiac patients on NOACs
- Unstable angina and non-ST elevation myocardial infarction (management of patients with)
- Prevention of Hospital Acquired Venous Thromboembolism
- Use of Treatment Dose Low Molecular Weight Heparin and Unfractionated Heparin
- Deep vein Thrombosis (DVT) The management of patients with suspected and confirmed DVT in the Acute Assessment Unit
- Pulmonary Embolism (PE) The management of patients with suspected and confirmed PE in the Acute Assessment Unit
- The Diagnosis and Management of Heparin induced Thrombocytopenia
- Peri-operative Management of patients on Anti-coagulant and Anti-platelet Agents
- Blood Transfusion Policy

Please refer to the above policies/guidelines for information in relation to these specific medicines/treatments.

1. WARFARIN GUIDANCE

Initiation

Before starting anticoagulation, check: FBC, U+E, LFTs and coagulation screen **Warfarin is prescribed on MedChart under the variable dose tab.**

Venous Thromboembolism

Concomitant treatment with LMWH/UFH (bridging) is required for patients with/at high risk of developing venous thromboembolism. Treatment dose LMWH or unfractionated heparin is usually required for 5-7 days until INR is within therapeutic range.

Daily INRs **MUST** be performed for the first four days of treatment.

Warfarin Induction Dosage Chart for Venous Thrombosis

Based on Fennerty et al 1984 and Gedge at al 2000. *Risk factors: Age >70 years, Liver impairment, Low albumin <36g/L, Weight <60kg, Parenteral feeding, Increased bleeding risk, CCF, COPD, interacting medicines

	INR Value in Patients Warfarin dose INR Value in Warfarin dose				
Day	<pre></pre>		Patients with		
	<10 years	(mg)	risk factors*	(mg)	
1	-1.1	10		10	
1	<1.4	10	<1.4	10	
2	<1.8	10	<1.8	5.0	
	1.8	1	1.8-2.0	1.0	
•	>1.8	0.5	>2.0	0	
3	<2.0	10	<2.0	5	
	2.0-2.1	5	2.0-2.5	4	
	2.2-2.3	4.5	2.6-2.9	3	
	2.4-2.5	4	3.0-3.2	2	
	2.6-2.7	3.5	3.3-3.5	1	
	2.8-2.9	3	>3.5	0	
	3.0-3.1	2.5			
	3.2-3.3	2			
	3.4	1.5			
	3.5	1			
	3.6-4.0	0.5			
_	>4.0	0		_	
4	<1.4	8	<1.4	7	
	1.4	8	1.4-1.5	7	
	1.5	7.5	1.6-1.7	6	
	1.6-1.7	7	1.8-1.9	5	
	1.8	6.5	2.0-2.3	4	
	1.9	6	2.4-3.0	3	
	2.0-2.1	5.5	3.1-3.2	2	
	2.2-2.3	5	3.3-3.5	1	
	2.4-2.6	4.5	3.6-4.0	0	
	2.7-3.0	4			
	3.1-3.5	3.5		0 1 1	
	3.6-4.0	3	>4	Seek advice	
	4.1-4.5	Miss next dose			
		then 2mg			
	>4.5	Miss 2 doses			
		then 1mg			

FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101

<u>Warfarin Induction Dosage Chart for Atrial Fibrillation</u> Patients starting warfarin for AF do NOT need bridging with LMWH. Unless they have valve replacements or are at high risk of developing VTE (CHADS >5).

Day	INR	Dose	Interval (days) to next test
1	0.0-1.3	2mg	14
15	1.0	6mg	7
15	1.1-1.2	5mg	7
15	1.3-1.5	4mg	7
15	1.6-2.1	3mg	7
15	2.2-3.0	2mg	7
15	3.1-4.0	1mg	7

AF - induction for patients requiring early cardioversion (Ageno 2003)

Day	INR	Dose	Interval (days) to next test
1	0.0-1.3	5	1
2	0.0-1.4	5	1
2	1.5-1.9	2.5	1
2	2.0-2.4	1	1
2	2.5-5.0	0	1
3	0.0-1.4	5	1
3	1.5-1.9	2.5	1
3	2.0-2.4	1	1
3	2.5-5.0	0	1
4	0.0-1.3	7.5	1
4	1.4-1.9	5	1
4	2.0-2.9	2.5	1
4	3.0-3.4	1	1
4	3.5-5.0	0	1
5	0.0-1.3	10	1
5	1.4-1.7	7.5	1
5	1.8-2.4	5	1
5	2.5-3.0	2.5	1
5	3.1-3.5	1	1
5	3.6-5.0	0	1

Recommended Therapeutic INR Targets and Duration

Indication	INR target	Suggested Duration
Pulmonary Embolus	2.5	6 months
Distal DVT due to temporary risk factors	2.5	3 months
Isolated Calf vein DVT	2.5	6 weeks
Proximal DVT or DVT of unknown cause or those associated with on-going risk factors	2.5	3 months then review
Venous Thromboembolism associated with malignancy	2.5	6 months then review
Recurrence of VTE—NOT on Warfarin	2.5	Long term
Recurrence of VTE—WHILST on Warfarin	3.5	Long term
Atrial fibrillation	2.5	Long term
AF for cardioversion	3.0	3 weeks pre-cardioversion at least, 4 weeks post
Cardiomyopathy	2.5	Long term
Mural thrombus	2.5	3 months
Rheumatic mitral valve disease	2.5	Long term
Mechanical prosthetic heart valves (Low thrombogenicity) Aortic carbomedics, Medtronic Hall, St Jude Medical	2.5 (3.0†)	Long term
Mechanical prosthetic heart valves (Medium thrombogenicity) Bjork-Shiley, other bileaflet	3.0 (3.5†)	Long term
Mechanical prosthetic heart valves (High thrombogenicity) Starr-Edwards, Omniscience, Lillehei-Kaster	3.5	Long term
Antiphospholipid syndrome	2.5	Long term
Peripheral Vascular disease (acute arterial embolism proceeding to embolectomy)	2.5	Long term

† Patient related risk factors: Mitral, tricuspid, pulmonary position. Previous arterial thromboembolism, atrial fibrillation, left atrial diameter >50mm; mitral stenosis; left atrial ejection fraction <35%; left atrial dense spontaneous echo contrast

Dosage Management and Monitoring

The warfarin dose required to achieve full anticoagulation will vary for each individual patient. It is important to confirm the maintenance dose for patients taking warfarin prior to admission. This information can be obtained from: the patient/carer, their yellow NPSA book or postal dosage slip or the anticoagulation clinic managing their warfarin.

Patients in Bedfordshire will have their warfarin managed by one of the following:

- Bedford Warfarin Service (01234 893413)
- BHT Anticoagulation Clinic ext. 2207, Bleep 467
- OR Patients' own GP

Patients can receive their dosing schedule in their yellow book or via a Postal Dosage Slip (see below).

INR testing and managing out of range results

INR testing should be tested at least once or twice a week during the initial stages of treatment. Once the maintenance dose is established and the INR remains in the therapeutic range, the interval between testing can be increased. The maximum testing interval is 12 weeks.

INR should be tested more frequently (daily/twice a week), when a medication is started/stopped, when the warfarin dose is changed or (for inpatients) if the clinical condition changes.

There are many factors than can destabilise a patients INR including:

- Over/under dosing
- Drug interactions (Prescribed medicines, OTC and herbal medicines)
- Use of alcohol or drugs.
- Factors affecting absorption (e.g. gut oedema)
- Factors affecting distribution (e.g. albumin)
- Factors affecting metabolism (e.g. hyperthyroidism)
- Food and drink intake (e.g. green vegetables and cranberry juice).

In patients with an INR outside the therapeutic range, a dose adjustment will be required. The size of the adjustment will be determined by the deviation of INR from the target, the presence or otherwise of any destabilising factors or known risk factors for haemorrhage/VTE and the ease of monitoring the patient.

In general, when adjusting the dose, a 15% change in dose is expected to result in a change in the INR of 1, and a 10% dose adjustment is expected to result in a 0.7–0.8 change in the INR. Dose adjustments should be increased or decreased by looking at the **weekly** dose not the daily dose.

Sub-therapeutic INRs

Depending on the INR, the warfarin dose may need to be (temporarily) increased, and sometimes a booster dose may be required (25-50% of the maintenance dose for 1 -2 days) — the INR should then be measured 2 or 3 days later to ensure that it is increasing. If the patient is at high risk of developing a VTE then LMWH cover may be necessary. *High INRs*

If the INR is less than 0.5units above the target value (i.e. INR target range is 2-3 and INR is 3.4), withholding doses is **NOT** necessary and a temporary dose reduction may suffice. Destabilising/risk factors must be taken into account and INR retested in 2-3 days. See Appendix 15 – Management of over anticoagulation and reversal of bleeding.

If INR remains poorly controlled (TTR <65%) then consider switching to another anticoagulant.

FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101

Postal Dosage Slip

	Private & Confidential	
	Mrs Test Test	Bedford Hospital NHS Trust
.	TO OPEN: CUT OR FOLD AND CU	IT ALONG THE PERFORATIONS
t	NAME: Mrs Test Test DOB: 19/06/2015 NHS NUMBER: CONDITION REQUIRING ANTICOAGULATION : - Atrial Fibrillation DURATION OF TREATMENT: Indefinite TARGET INR :- 2.0 - 3.0 (2.5 Target) ANTICOAGULANT NAME :- PLEASE TEST BEFORE 12.00 MIDDAY	Your INR and dose instructions are: Date of INR: 16/05/2018 INR: 2.5 Varfarin Sun Mon Tue Wed Thu Fri Sat ng 4 3 3 3 4 Next test: 23/05/2018 INR Dose Dose Dose
0	BEDFORD HOSPITAL NHS TRUST - TELEPHONE	
Dedeparable: Nik. +++ (B)1:348 540000 Examit requires the datagraphic co.sk.	INR BLOOD TEST REQUEST FORM (Please tear of HOSPITAL NUMBER: 123654 NHS NUMBER: SURNAME: Test FORENAME: Test DOB: 19/06/2015 CONTACT NUMBER: GP NAME AND ADDRESS: Dr	f) IMPORTANT INFORMATION (Please Circle) Since your last INR blood test have you: Had any bruising or bleeding? YES/NO Missed any doses of anticoagulants? YES/NO Taken a different dose to the recommended dose? YES/NO Started or stopped any other medicines? YES/NO Been in hospital? YES/NO If you answered "Yes" please give details such as name and dates of when you were in hospital.
	TARGET INR :- 2.0 - 3.0 (2.5 Target) Person taking blood sample to complete Sample Date Time	

2. DISCHARGE OF INPATIENTS TAKING ANTICOAGULANTS

It is the prescriber's responsibility to make sure that the following are documented on the discharge letter:

- Indication for anticoagulation
- Date of initiation (if newly started during current admission)
- Dosage (until follow up appointment with anticoagulation clinic)
- Required duration
- Target INR (Warfarin only)

<u>Warfarin</u>

INR should be therapeutic on discharge. It is the clinical teams' responsibility to dose the patient until their next scheduled anticoagulation appointment this will be done in their Yellow Book (issue a new one for patients who have not brought theirs in or usually have postal dosage slips).

The nurse looking after the patient MUST arrange the follow up appointment before discharge with the relevant GP surgery or clinic.

Particular care should be taken when discharging patients close to the weekend or public holidays to ensure blood tests can be arranged at an appropriate interval after discharge. For VTE patients, it may be safer to discharge on therapeutic tinzaparin and refer to anticoagulation clinic for warfarin loading than to load during the inpatient stay and discharge prior to day 4.

All patients taking warfarin pre-admission should be re-referred back to the clinic they were originally managed by:

- Bedford Warfarin Service via telephone 01234 893413
- BHT Anticoagulation Clinic send referral form (Appendix 9) to POD18, ext. 2207, Bleep 467
- OR Patients' own GP

Patients **newly started** on warfarin should be referred to the BHT Anticoagulation Clinic. The prescribing doctor MUST complete the Oral Anticoagulation Referral form (Appendix 9)

A 'Warfarin Discharge Checklist' must be completed by the nurse looking after the patient and filed in the medical notes.

Patients requiring administration of tinzaparin should be referred to the Ambulatory Emergency Care Unit (ext 6331/6337) for daily administration and INRs.

Where patients have undergone day case procedures a full referral is not required. However, to ensure continuity of care the anticoagulant services should receive notification of the procedure that has been carried out and any changes that were made to the patients' anticoagulation.

Out of area patients

Patients under the care of GPs outside of Bedfordshire should have a referral made to their local secondary care anticoagulation clinic.

NOACs

Inpatients **newly started** on NOACs should be counselled appropriately. The nurse/pharmacy staff looking after the patient must complete the NOAC checklist (see below) and file in the medical notes. Patients can also be referred to the Anticoagulation Clinic for a follow up counselling appointment post discharge. Complete the referral form in Appendix 9 and send to Anticoagulation Clinic POD 18.

Tinzaparin

Patients must be supplied with a sufficient amount of syringes, appropriately counselled on administration on injection technique and given a sharps bin for disposal. Refer to AECU as above if necessary.

Patient Education, Counselling and documentation

Patients discharged on anticoagulants must be appropriately counselled so they understand the high risk nature of the medication and the importance of compliance (See warfarin and NOAC checklists below).

Patients should receive:

NPSA Yellow Warfarin information Pack (new *warfarin patients only*) Yellow warfarin dosing book - containing dosing instructions up until anticoagulant clinic follow up appointment. In-house patient information leaflets Oral Anticoagulant Alert card

Dosette boxes

Warfarin, Apixaban, Edoxaban and Rivaroxaban can be used in compliance aids. Dabigatran is not suitable for compliance aids.

Letter to Primary Care

On initiation of a NOAC, clinicians should write an informative letter to Primary Care regarding future prescribing and monitoring.

Example letters to primary care can be found in the Appendices of the following guidelines: <u>Non Vitamin K Antagonist Oral Anticoagulants (NOACs) in Non-Valvular Atrial Fibrillation:</u> <u>Initiation of treatment</u>

<u>Deep vein Thrombosis (DVT) – The management of patients with suspected and confirmed</u> <u>DVT in the Acute Assessment Unit</u>

Pulmonary Embolism (PE) - The management of patients with suspected and confirmed PE in the Acute Assessment Unit

Bedford Hospital

NHS Trust

WARFARIN DISCHARGE CHECKLIST (For Nurses Use)

Patient Name: Hospital Number: (or addressograph) Ward: Consultant:

Date of discharge:

Please fill and sign ALL sections on completion of each task, and file in medical notes with TTO.

Oral Anticoagulant Therapy/Yellow Book completed (In particular: patient's ID, dose, next test date & venue and tinzaparin details if needed)	(tick)	Nursing staff (sign)
Are there any safety concerns? YES/NO	_	
- state:	(tick)	
If YES, contact the appropriate person		
On discharge patient's warfarin will be dosed/managed by:		
	(tick)	Nursing staff
 Bedford Hospital Anticoagulation Clinic 		(sign)
 complete "Anticoagulation Referral Form" and procedure 		
 Bedford Warfarin Clinic 		
 call 01234 317182 to arrange F/U appointment 		
 General Practitioner 		
 call patient's GP surgery to arrange F/U appointment 		
 Bedford Hospital AECU – for patients requiring Tinzaparin on discharge 		
 call Ext. 6331/6337 to arrange F/U appointment 	브	
Others (e.g. other hospitals) - state:		
 call the relevant clinic to arrange F/U appointment 		
Patients must be reminded to present their discharge letters to the staff at their F/U app	ointment.	
Is daily tinzaparin for warfarin bridging required? YES/NO – if YES find out if:		
Patient / Carer administering		Nursing staff
 Correct and sufficient pre-filled syringes (dispensed from pharmacy) and sha provided; patient/carer understands treatment duration and injectiontechniques) 		(sign)
 Bedford Hospital AECU administering 	_	
 Referral is completed and transport is booked if needed. 		
GP Surgery administering		
 Referral is completed and correct and sufficient pre-filled syringes or vials di pharmacy are provided. 	spensed by	
District Nurse administering		
 Referral is completed and correct and sufficient pre-filled syringes or vials di 	spensed by	
pharmacy are provided.		
Patients / Carers are counselled on:		
Strength of tablets they have been prescribed and dispensed		Nursing staff
How many tablets and milligrams they need to take each day		(sign)
Time and place where their next INR test is scheduled	н	
Our size also state faile fallow web		
Queries about warfarin follow-up? Contact Anticoagulation Administrat	tor Ext 2207	

Patient Name: Hospital/NHS Number:

(or attach addressograph)

Ward:

Bedford Hospital NHS Trust

NOAC (Non vitamin K antagonist oral anticoagulant) INITIATION CHECKLIST This checklist is for patients taking apixaban (Eliquis®) edoxaban (Lixiana®) or rivaroxaban (Xarelto®)

maintenance dose.(refer to medical notes/TTO letter for dosing schedule) Importance of adherence and persistence with treatment • Fairly rapid fall in drug levels (and therefore loss of effective ness) if poorly compliant • Discuss ways of remembering to take. • Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider		Tick	Nursing / Pharmacy staff (sign)	Doctors (sign)
Clinical Indication Estabilish the indication, note in space	NOAC treatment commenced prior to discharge			
Establish the indication patient is taking the NOAC for (AF/DVT/PE) if taking if taking for other indication, note in space	NOAC treatment to be commenced by GP/Other after discharge			
If taking for other indication, note in space	Clinical Indication			
Is the patient on an Antiplatelet therapy (Appint/Oppidget) Is this cilinically indicated? (Appint/Oppidget) Is this cilinically indicated? (Appint/Oppidget) If previously on warfarin ensure this has been discontinued. Counselling information Patient/Carer administering (ensure NOAC patient information leafer is provided to core/patient) Does and Frequency check Administration information: Alwaroxaban MUST be taken with or without food Rivaroxaban MUST be taken with or without food Rivaroxaban MUST be taken with of the maintee absorption If taking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose. <i>Information</i> Fishing for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose. <i>Information</i> Fishing for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose. <i>Information</i> Fishing for newly diagnosed PE/DVT patient is aware to when to commence on the maintenance dose. <i>Information</i> Fishing for newly diagnosed PE/DVT patient is aware bow thoreatment Fishing for newly diagnosed Der/DVT patient for deaing scheduk) Importance of adherence and persistence with treatment Fishing take with or dra resupply from GP What to do if a dose is missed -If unsure, talk to healthcare provider If a dose is missed take usual time. Tous: virvorxaban and acute VTE) Once daily dosing: take within 6 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. Tous: virvorxaban 15mg twice daily (buttan take 2A: Sing at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment toke (<i>ref</i> to medican ecort70 later) Potential for drug interactions: avoid DTC mediches containing aspirin (e.g. flur remedies), NSADs or herbals. Pracetamol is the preferred analgesic. Pt to inform healthcare professional of any new meds. Musta to do life beeding or builing or builing or builing or treatment e.g. Drs, Dentists & Pharmacits. Mintoring and Review Reassure	Establish the indication patient is taking the NOAC for (AF/DVT/PE) if taking			
(Appint/Copidegref) Intervention of the second	If taking for other indication, note in space			
(Appint/Copidegref) Intervention of the second				
is this clinically indicated? (check marked note/heak with preacher) (free/marked/note/heak with preacher) (rearve NOA/C patient information ledget is provided to carer/patient) Dose and Frequency Check Administration information: A physiaba and Edoxaban can be taken with or without food • Rivaroxaban MUST be taken with food to maximize absorption If taking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose./refer to marked note of the for daming schedulo) Importance of adherence and persistence with treatment • Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant • Discus ways of remembering to take. • Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider • If a dose is missed take it usato of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • Twice daily dosing: take within12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • NUTE: *riveroxaban 15 mg twice daily (buct vTE): take one tablet as soon as remembered. Do not take more than two 15 mg tabs in a single day (buct an take 2x15 mg at the same time to make a total of 30 mg on one day). Continue with 15 mg twice daily (buct an take 2x15 mg at the same time to make a total of 30 mg on one day). Continue with 15 mg twice daily (buct an take 2x15 mg at the same time to make a total of 30 mg on one day). Continue with 15 mg twice daily the following day Duration of treatment check (<i>refer to maded notexrTTO letter</i>) Potential for drug interactions: awold OTC mediones containing aspirin (e.g. flu remedies), NABDo or horbals. Paracetamol is the preferred analgesic. Pt to inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (<i>minor bleeding or bruising occurs</i>) • Patient issued/alreadyhas a NOAC alert card and advised to carry at all time. (<i>Fill in as much detail</i> <i></i>	Is the patient on an Antiplatelet therapy			
(check medical -macy doed with practice) If previously on warfarin ensure this has been discontinued. Conselling information Patient /Carrer administering (ensure NACE patient information leafet is provided to carer/patient) Does and Frequency check Administration information: • Apixaban and Edoxaban can be taken with or without food • Rivaroxaban MUST be taken with food to maximize absorption If taking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose, <i>lefer to medical notes</i> /TTO <i>letter for dasing schedule</i>) Importance of adherence and persistence with treatment • Fairity rapid fail in drug levels (and therefore loss of effectiveness) if poorly compliant • Discuss ways of remembering to take. • Ensure patient is aware how to order a resupply from GP What to do if a dose is missed -lifu surver, talk to healthcare provider • If a dose is missed -lifu surver, talk to healthcare provider • If a dose is missed -lifu surver, talk to healthcare provider • If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for rivaroxaban and acute VTE) • Once daily dosing: take within 2 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • Twice daily dosing: take within 2 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time.				
if previously on warfarin ensure this has been discontinued. Counselling information Patient/Carer administering (ensure NOAC patient information leafet is provided to carer/patient) Dose and Frequencycheck Administration information:				
Counselling information Patient/Carer administering (ensure NOAC patient information leafet is provided to carer/patient) Does and FrequencyCheck Administration information: • Apixaban and Edoxaban can be taken with or without food • Apixaban and Edoxaban can be taken with or without food • Apixaban and Edoxaban can be taken with or maximize absorption • If taking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose, <i>lefer to medical noter/TTO letter for dasing schedule</i>) Importance of adherence and persistence with treatment • Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant • Discuss ways of remembering to take. • Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, taik to healthcare provider • If a dose is missed take it tas soon as possible. Do not take a double dose* (but see below for rivaroxaban and acute VTE) • Once daily dosing: take within 12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • NOTE: * frivenoxaban 15m givice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15m gtabs in a single day (but can take 2x15m gt the same time to make atotal of 30mg on one day). Continue with 15m gtwice daily the following day Duration of treatment check (<i>refer to medical noter/TTO letter</i>) • Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSADs or herbals. Paracetamol is the preferred an				
Patient/Carer administering (ensure NDAC patient information leaflet is provided to carer/patient) Dose and Frequency check Administration information: • Apixaban and Edoxaban can be taken with or without food • Rivaroxaban MUST be taken with food to maximize absorption If taking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose./pdf to madical netw(TTO letter for dosing schedule) Importance of adherence and persistence with treatment • Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant • Discuss ways of remembering to take. • Ensure patient is aware how to order a resupply from GP What to do if a dose is missed -If unsure, talk to healthcare provider • If a dose is missed take within12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • Twice daily dosing: take within16 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. • NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (butcan take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical notes/TTO letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSADs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare p				
(ensure NOAC patient information leafer is provided to carer/patient) Dose and Frequency check Administration information: • Apixaban and Edoxaban can be taken with or without food • Rivaroxaban MUST be taken with food to maximize absorption If taking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose. <i>leffer to madca naeer/TO leter for doaing schedule</i>) Importance of adherence and persistence with treatment • Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant • Discuss ways of remembering to take. • Ensure patient is aware how order a resupply from GP What to do if a dose is missed - furusure, talk to healthcare provider • If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for riveroxaban and acute VTE) • Once daily dosing: take within 12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • Twice daily dosing: take within 12 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. • Twice daily dosing take within 2 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. • Twice daily dosing take within 12 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. • Twice daily dosing take within 2 hours of missed dose, if more than 6 hours, omit the dose and then continue at				
Administration information: Apixaban and Edoxaban can be taken with or without food Rivaroxaban MUST be taken with food to maximize absorption Iftaking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose.(refer to medical notex/TTD letter for daving schedule) Importance of adherence and persistence with treatment Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant Discuss ways of remembering to take. Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for riveroxaban and acute VTE) Once daily dosing: take within 12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical notex/TTD letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding anal/t69/111, mgior bleeding ge to A&E) Patient issued/alreadyhas a NOAC alert card and advised to carry at all time. (
Apixaban and Edoxaban can be taken with or without food Rivaroxaban MUST be taken with food to maximize absorption If taking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose. (refer to medical notes/T70 letter for dasing schedule) Importance of adherence and persistence with treatment Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant Discuss ways of remembering to take. Ensure patient is aware how to order a resupply from GP What to do if a dose is missed -lifunsure, talk to healthcare provider If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for rivaroxaban and acute VTE) Once daily dosing: take within 2 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabls in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical noter/T70 letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSADs or horbals. Paracetamol is the preferred analgesic. Pt to inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding on bruising occurs (minor bleeding on ther HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.	Dose and Frequencycheck			
Rivaroxaban MUST be taken with food to maximize absorption If taking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose. <i>Infer to matical notex/TTO letter for dasing schedule</i>) Importance of adherence and persistence with treatment Pairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant Discuss ways of remembering to take. Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for rivaroxaban and acute VTE) Once daily dosing: take within 12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (<i>refer to madical notex/TTO letter</i>) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSADs or herbals. Paracetamol is the preferred analgesic. Pt to inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (<i>minor bleeding aon uLSP</i>) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.	Administration information:			
If taking for newly diagnosed PE/DVT patient is aware of when to commence on the maintenance dose./refer to medical notes/TTO letter for dosing schedule) Importance of adherence and persistence with treatment • Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant • Discuss ways of remembering to take. • Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider • If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for rivaroxaban and acute VTE) • Once daily dosing: take within12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • Twice daily dosing: take within6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (<i>refer to medical notes/TTO letter</i>) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding consult GP/111, mejor bleeding go to A&E) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & P	 Apixaban and Edoxaban can be taken with or without food 			
maintenance dose./refer to medical notes/TTO letter for dosing schedule) Importance of adherence and persistence with treatment • Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant • Discuss ways of remembering to take. Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider • If a dose is missed take it as soon as possible. Do not take a double dose * (but see below for rivaroxaban and acute VTE) • Once daily dosing: take within 2 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • NOTE: * rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical notes/TTO letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding consult GP/111, meior bleeding consult GP/111, meior bleeding consult GP/111, meior bleeding op to A&E) • Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular an	 Rivaroxaban MUST be taken with food to maximize absorption 			
Importance of adherence and persistence with treatment • Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant • Discuss ways of remembering to take. • Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider • If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for rivaroxaban and acute VTE) • Once daily dosing: take within12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. • NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (<i>refer to medical notes/TTD letter</i>) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (<i>minor bleeding onsult GP/111, major bleeding go to A&E</i>) • Patient issued/already has a NOAC alert card and advised to carry at all time. (<i>Fill in as much details you can</i>) • Patient should be advised to inform other HCPs they are visiting fo	If taking for newly diagnosed PE/DVT patient is aware of when to commence on the			
Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant Discuss ways of remembering to take. Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider If a dose is missed - If unsure, talk to healthcare provider If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for rivaroxaban and acute VTE) Once daily dosing: take within 12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (<i>refer to medical notes/TTO letter</i>) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Pt to inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (<i>minor bleeding on ult GP</i> /111, <i>mgior bleeding os to A&E</i>) Patient issued/already has a NOAC alert card and advised to carry at all time. (<i>Fill in as much detail</i> you can) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.	maintenance dose. (refer to medical notes/TTO letter for dosing schedule)			
Fairly rapid fall in drug levels (and therefore loss of effectiveness) if poorly compliant Discuss ways of remembering to take. Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider If a dose is missed - If unsure, talk to healthcare provider If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for rivaroxaban and acute VTE) Once daily dosing: take within 12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (<i>refer to medical notes/TTO letter</i>) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Pt to inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (<i>minor bleeding on ult GP</i> /111, <i>mgior bleeding os to A&E</i>) Patient issued/already has a NOAC alert card and advised to carry at all time. (<i>Fill in as much detail</i> you can) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.	Importance of adherence and persistence with treatment			
Discuss ways of remembering to take. Ensure patient is aware how to order a resupply from GP What to do if a dose is missed - If unsure, talk to healthcare provider If a dose is missed take it as soon as possible. Do not take a double dose * (but see below for rivaroxaban and acute VTE) Once daily dosing: take within12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical notes/TTO letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding on buil GP/111, mgior bleeding og to A&E) Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in as much detail you can) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists.				
What to do if a dose is missed - If unsure, talk to healthcare provider • If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for rivaroxaban and acute VTE) • Once daily dosing: take within12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. • Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical notes/TTO letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding consult GP/111, mgior bleeding go to A&E) Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in as much detail you can) • Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in as much detail you can) Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in as much detail you can) • Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review				
 If a dose is missed take it as soon as possible. Do not take a double dose * (but see below for rivaroxaban and acute VTE) Once daily dosing: take within12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: * rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (<i>refer to medical notes/TTO letter</i>) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (<i>minor bleeding gon to A&E</i>) Patient issued/already has a NOAC alert card and advised to carry at all time. (<i>Fill in cs much detail you can</i>) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. 	 Ensure patient is aware how to order a resupply from GP 			
rivaroxaban and acute VTE) Once daily dosing: take within12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical notes/TTO letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding consult GP/111, mgior bleeding go to A&E) Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in as much details you can) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.	What to do if a dose is missed - If unsure, talk to healthcare provider			
Once daily dosing: take within12 hours of missed dose, if more than 12 hours, omit the dose and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: * rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (<i>refer to medical notes/TTO letter</i>) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (<i>minor bleeding consult GP/111, mgior bleeding go to A&E</i>) Patient issued/already has a NOAC alert card and advised to carry at all time. (<i>Fill in as much details</i> <i>you can</i>) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.	 If a dose is missed take it as soon as possible. Do not take a double dose* (but see below for 			
and then continue at the usual time. Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical notes/TTO letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding consult GP/111, major bleeding go to A&E) Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in comuch details you can) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.				
Twice daily dosing: take within 6 hours of missed dose, if more than 6 hours, omit the dose and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (<i>refer to medical notes/TTO letter</i>) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (<i>minor bleeding consult GP/111, major bleeding go to A&E</i>) • Patient issued/already has a NOAC alert card and advised to carry at all time. (<i>Fill in as much detail</i> <i>you can</i>) • Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.				
and then continue at the usual time. NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (<i>refer to medical notes/TTO letter</i>) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (<i>minor bleeding consult GP/111, major bleeding go to A&E</i>) • Patient issued/already has a NOAC alert card and advised to carry at all time. (<i>Fill in as much detail</i> <i>you can</i>) • Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.				
NOTE: *rivaroxaban 15mg twice daily (acute VTE): take one tablet as soon as remembered. Do not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical notes/TTO letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding consult GP/111, major bleeding go to A&E) • Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in as much details you can) • Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.				
not take more than two 15mg tabs in a single day (but can take 2x15mg at the same time to make a total of 30mg on one day). Continue with 15mg twice daily the following day Duration of treatment check (refer to medical notes/TTO letter) Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Pt to inform healthcare professional of any new meds. What to do if bleeding or bruising occurs (minor bleeding consult GP/111, major bleeding go to A&E) • Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in as much details you can) • Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.				
make a total of 30mg on one day). Continue with 15mg twice daily the following day				
Duration of treatment check (refer to medical notes/TTO letter) Image: Comparison of the state of the				
Potential for drug interactions: avoid OTC medicines containing aspirin (e.g. flu remedies), NSAIDs or herbals. Paracetamol is the preferred analgesic. Ptto inform healthcare professional of any new meds. Image: Content of the con				
NSAIDs or herbals. Paracetamol is the preferred analgesic. Pt to inform healthcare professional of any new meds. Image: Comparison of the state of the sta				
of any new meds. Image: Constraint of the constraint of				
(minor bleeding consult GP/111, major bleeding go to A&E) Image: consult GP/111, major bleeding go to A&E) • Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in as much details you can) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. • Monitoring and Review Monitoring and Review				
Patient issued/already has a NOAC alert card and advised to carry at all time. (Fill in as much details you can) Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.	What to do if bleeding or bruising occurs			
you can) • Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.				
Patient should be advised to inform other HCPs they are visiting for treatment e.g. Drs, Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.				
Dentists & Pharmacists. Monitoring and Review Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.				
Reassure patient that there is no requirement for regular anticoagulant monitoring with NOAC.				
	Monitoring and Review			
or snould check kuney junction at roc at least annually or more frequently if clinically indicated.)				
	(or snould check kaney function & roc at least annually or more frequently if clinically indicated.)			

3. ANTICOAGULATION REFERRAL FORM



Switching to:

Anticoagulation Referral Form

Please ensure the patient is given a prescription for relevant anticoagulant and an appointment at the time of referral. NOTE: ANTICOAGULATION CONTROL WILL BE THE RESPONSIBILITY OF THE REFERRING CLINICIAN UNTIL REVIEW IN THE ANTICOAGULATION CLINIC

Mon – Fri 9 am – 4 pm. TEL: 01234795736 EXT: 2207 / FAX: 01234792148 / BLEEP 467

 Patient details: (Affix addressograph here)
 New Referral []
 Reason for Referral: Warfarin Initiation / Monitoring []

 Re-Referral []
 Warfarin Initiation / Monitoring []

 NOAC Counselling []

 Switch from NOAC to Warfarin []

 Current Anticoagulant Please (v) tick as appropriate
 Warfarin []

 Image: Note of the second seco

Date Anticoagulation started: / / Current Dose:

INDICATION for Anticoagulation	(√) Tick	TARGET	DURATION	INDICATION for Anticoagulation	(√) Tick	TARGET	DURATION
Pulmonary Embolism		2.5	3 months	Atrial Fibrillation		2.5	LongTerm
Recurrent Pulmonary Embolism		2.5	Long Term	(non-valvular)			
Pulmonary Embolism (whilst on anticoagulation)		3.5	Long Term	AF for cardioversion		3.0	3 weeks prior, 4 weeks post.
CalfDVT		2.5	6 weeks	Proximal DVT		2.5	3 months
RecurrentDVT		2.5	Long Term	Cardiomyopathy		2.5	Longterm
Recurrent DVT (whilst on anticoagulation)		3.5	Long Term	Mural Thrombus		2.5	LongTerm
VTE associated with malignancy		2.5	6 months then review	Rheumatic Mitral Valve disease		2.5	Long Term
Mechanical prosthetic heart		2.5	Long Term	Peripheral Vascular disease		2.5	LongTerm
valves (depending on		3.0		(acute arterial embolism proceeding to embolectomy)			
thrombogenicity: see guidelines- Appendix 7)		3.5		to empolectomy			
Tissue Prosthetic Heart Valve		2.5	3 months and review	Other (Please Specify)			

See overleaf for scoring system	Is patient on LMWH: Yes 🗖 No 🗖
CHA2DS2VASc Score(AF pts only): HASBLED Score:	
Coagulation Screen / LFTs / U&Es checked: Yes / No CrCl (ml/min):	Which LMWH:
Is national on Association 🗖 Classiciansel 🗖 Other	Dose:
Stee Assision when INP >2.0 Vec 🗖 No 🗖 (See quidelines)	Date started: / /

Oral Anticoagulation History (Warfarin/Phenindione/ Other__

Recent dosing history:

Clinical Information

Past Medical History & Other Medications:

-)

Ward: Bleep: Date:

DATE	INR	DOSE

Name of Referring Clinician:

Consultant responsible for patient

Clinic Appointmenton _____ Time: ____:_

Is transport required?			District nurse required?		
(ward to arrange for 1 $^{\rm sc}$ visit for inpatient)	Yes 🗆	No 🗆	(ward to arrange for 1 st visit for inpatient)	Yes 🗆	No 🗆
Anticongulation Deferral Form (Anticongula	tion1/July 7/	14 Q Marcian 4	0		

Anticoagulation Referral Form/Anticoagulation)/July 2018 Version 1.0

Reverse of Anticoagulation Referral Form

	CHA ₂ DS ₂ VASc Score – clinical characteristics:	Points
С	Congestive heart failure (or left ventricular systolic dysfunction)	1
Н	Hypertension: blood pressure consistently above 140/90mmHg (or treated hypertension on medication)	1
A ₂	Age ≥75 years	2
D	Diabetes Mellitus	1
S ₂	Prior Stroke or TIA or thromboembolism	2
V	Vascular disease (e.g. peripheral artery disease, myocardial infarction, aortic plaque)	1
Α	Age 65-74 years	1
Sc	Sex - Female	1

	HAS-BLED Score – clinical characteristics:	Points
Н	Hypertension	1
Α	Abnormal renal and liver function (1 point each)	1 or 2
S	Stroke	1
В	Bleeding	1
L	Labile or unstable INRs	1
E	Elderly (> 65 years)	1
D	Drug or alcohol (1 point each)	1 or 2

Reverse of Anticoagulation Referral Form

4. SWITCHING BETWEEN ANTICOAGULANTS

		SWITCHING	BETWEEN ANTICOA	GULANTS		
To→ From↓	Warfarin	LMWH	Apixaban	Edoxaban	Rivaroxaban	Dabigatran
Warfarin		Stop warfarin and start LMWH when INR < 2.0 In patients with high risk of thrombosis consider starting when INR <3.0	Stop warfarin. If INR<2 start. If INR 2-2.5 start the next day	Stop warfarin. If INR < 2 start. If INR 2-2.5 start the next day	Stop warfarin. If INR <2 start. If INR 2-2.5, start the next day	Stop warfarin. If INR <2 start. If INR 2-2.5, start the next day
LMWH	Start warfarin in combination with LMWH and monitor INR. Discontinue LMWH when INR in therapeutic range for 2 consecutive days		Start when next dose is due	Start when next dose is due	Start when next dose is due	Start when next dose is due
Apixaban	Start warfarin. Do not stop apixaban. Consider measuring INR daily until in range then stop Apixaban (~2 days)	Start when next dose is due		Start when next dose is due	Start when next dose is due	Start when next dose is due
Edoxaban	If patient is taking: - 60 mg, prescribe 30 mg OD with warfarin. - 30 mg, prescribe 15 mg OD with warfarin. Consider measuring INR daily until in range then stop edoxaban	Start when next dose is due	Start when next dose is due		Start when next dose is due	Start when next dose is due
Rivaroxaban	Start warfarin. Do not stop rivaroxaban. Consider measuring INR daily‡ until in range then stop rivaroxaban	Start when next dose is due	Start when next dose is due	Start when next dose is due		Start when next dose is due
Dabigatran	Start warfarin*. Do not stop dabigatran. Consider measuring INR daily until in range then stop dabigatran	Start when next dose is due	Start when next dose is due	Start when next dose is due	Start when next dose is due	

Please note: Dabigatran and apixaban slightly increase INR, therefore if dabigatran and warfarin OR apixaban and warfarin are taken together a normal INR does not mean that the patient is fully anticoagulated.

‡INR should be tested just before next dose of Rivaroxaban as rivaroxaban can increase the INR.

*If CrCl >50ml/min start warfarin 3 days before stopping dabigatran, if CrCl 30-50ml/min start warfarin 2 days before stopping dabigatran

FINAL (Review: March 2021)

Ref - Anticoagulation Policy 0092101

Page 17 of 41

5. DRUG INTERACTIONS AND ADMINISTRATION IN PATIENTS WITH SWALLOWING DIFFICULTIES AND/OR ENTERAL FEEDING TUBES

Significant Drug Interactions with Warfarin –Mechanism and Management

Warfarin is metabolised by the liver via cytochrome P450. Certain drugs may increase or decrease the effect of **Warfarin** and the risk of bleeding/ thrombosis. Drugs that induce hepatic P450 enzymes reduce clearance of warfarin and vice versa. This guide is intended as a quick reference to highlight significant interactions between Warfarin and commonly prescribed and OTC medicines. It is not intended to be an exhaustive list. For further information, please refer to the medicines SPC (*www.medicines.org.uk*), BNF or contact the pharmacy department.

Drug Effect on		Clinical Importance	Management
	INR		
Allopurinol	↑ INR	Anticoagulant effects possibly enhanced	Monitor INR when initiated
Amiodarone	↑ INR	Occurs in most individuals after 2weeks and may persist for many weeks after stopping amiodarone	Monitor INR during and after. May need to reduce warfarin
Barbiturates (e.g. Phenobarbitol)	↓INR	Serious interaction- the effect of the barbiturates may persist for 6weeks after they have discontinued	Monitor INR warfarin dose may need to increased
Carbamazepine	↓ INR	Serious interaction –unpredictable	Monitor INR during and after, warfarin may need to be increased
Cholestyramine	↓/↑INR	Minimize effect by giving warfarin and cholestyramine doses 4- 6 hours apart	Monitor INR
Cimetidine	↑INR	Famotidine, nizatidine and ranitidine appear not to interact	Select an alternative H2 antagonist
Clarithromycin	↑INR	Potential serious interaction –however unpredictable and uncommon (also with Azithromycin)	Monitor INR on initiation and within 3 days of starting
Clopidogrel		↑ risk of bleed due to antiplatelet effect	Avoid concomitant use if possible
Dipyridamole	Unchanged or ↑INR	Increase risk of bleeding can occur with concurrent use due to antiplatelet effect	Monitor INR
Disulfiram	↑INR	Occurs in most individuals	Monitor on initiating & withdrawing
Erythromycin	^INR	Potential serious interaction –unpredictable, but most patients are unlikely to develop a clinically significant interaction	Elderly at greatest risk. Monitor closely within 3 days of starting.

FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101 Page 18 of 41

Fibrates (Clofibrate, Bezafibrate, Fenofibrate, Gemfibrozil)	↑INR	Serious interaction. Incidence between 20 and 100%, but prudent to assume that most individuals will demonstrate this interaction	Reduce Warfarin dose by a third to a half initially and adjust according to INR – monitor closely
Fluconazole	↑INR	Serious interaction. Occurs in most individuals	Monitor on initiating and stopping
Fluoxetine	↑INR	Isolated reports of raised INR and/or haemorrhage - unpredictable	Monitor INR and signs of altered anticoagulation
Glucagon	↑INR	Potential serious interaction but not for doses ≤ 30mg over 1 or 2 days.	Monitor INR and reduce warfarin dose
Itraconazole	↑INR	Isolated reports but clinically significant	Monitor closely
Ketoconazole	↑INR	Small number of reports in elderly patients	Monitor closely – esp. elderly
Metronidazole	↑INR	Potential serious interaction, although documentation is small.	Warfarin dose may need to be adjusted. Monitor closely
Miconazole(e.g. buccal gel)	↑INR	Avoid – potentially serious interaction.	Use Nystatin as an alternative
NSAIDS	↑INR	Unpredictable serious interaction, effect on platelet activity plus GI irritation can result in GI bleed	Anticoagulant effects possibly enhanced – monitor closely
Oral contraceptive		Generally avoid in thromboembolic disorders	Monitor closely
Paroxetine		Can increase the likelihood of bleed without affecting INR	Use with caution
Proton pump inhibitor (PPI) (lansoprazole, omeprazole)	↑INR	Anticoagulant effects possibly enhanced although interactions do not appear to be clinically significant.	Monitor INR
Quinolones (ciprofloxacin)	↑INR	Unpredictable	Monitor INR
Rifampicin/ Rifabutin	↓INR	Reduces anticoagulant effects within 5 to 7days and persists for a 2 to 5 week after discontinuation. Monitor closely.Warfarin dose may ne doubled or trebled the stopping use.	
Sertraline	↑INR	Low risk – Isolated reports of thrombocytopenia, abnormal bleeding or purpura.	Monitor INR
Simvastatin	↑INR	Possible enhanced anticoagulant effect (also with rosuvastatin)	Monitor initially & after dose change
Sulphinpyrazone	↑INR	Serious interaction-well established	Monitor INR and reduce warfarin
Sulphonamide(Co-trimoxazole)	↑INR	Serious interaction-well established	Monitor INR and reduce warfarin
Tamoxifen	↑INR	Occurs in some, but not all individuals	Monitor INR, reduce Warfarin dose as necessary (may require dose reduction of up to half)
Tricyclic Antidepressants	1∕,↓INR	Can cause fluctuation in INR- insufficient evidence	Monitor INR
Vitamin K	↓INR	Consider this interaction if patients are Warfarin resistant. Vitami health foods, food supplements, green tea.	in K may be present in enteral feeds,

FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101

Page 19 of 41

	NOAC Drug Interactions
All NOACS	Nonsteroidal anti-inflammatory drugs (NSAIDs) — increased risk of bleeding with concomitant use of NSAIDs and NOACs. The risk is thought to be greatest with NSAIDs that have a half-life greater than 12 hours (e.g. piroxicam). •Avoid concomitant use if possible. If concurrent use is unavoidable, an NSAID with a short half-life such as ibuprofen (2 hours) is preferred. •Advise the person that they should seek medical advice if they experience any unexplained bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, and blood in the urine or stools. Other anticoagulants (e.g. heparin, warfarin, NOACS) — there is an increased risk of bleeding if other anticoagulants are given with NOACs. Avoid concomitant use except when switching to or from warfarin treatment. Antiplatelets - there is an increased risk of bleeding with concomitant therapy; avoid concomitant use with NOACs, except on specialist advice.
	Carbamazepine, phenytoin, rifampicin, and St John's Wort — plasma concentration of NOACs are reduced by all of these drugs. All manufacturers of NOACs have advised that concomitant use should be avoided.
Apixaban	Itraconazole, ketoconazole, voriconazole, posaconazole, and HIV protease inhibitors (e.g. ritonavir) — the plasma concentration of apixaban is increased by all of these drugs as they are strong inhibitors of both CYP3A4 and P-glycoprotein (P-gp). The manufacturer of apixaban has advised that concomitant use should be avoided.
	Diltiazem, naproxen, amiodarone, verapamil, and quinidine are weak inhibitors of CYP3A4 and P-gp. However, no dose adjustment is needed when these drugs are co-administered with apixaban.
Edoxaban	Amiodarone, quinidine and verapamil— no dose reduction is required.
	Ciclosporin, dronedarone, erythromycin, itraconazole, and ketoconazole — the plasma concentration of edoxaban is increased by all of these drugs. The manufacturer has advised that the dose of edoxaban should be reduced to 30 mg daily.
Rivaroxaban	Ketoconazole, itraconazole, voriconazole, posaconazole, dronedarone, or HIV protease inhibitors — the plasma concentration of rivaroxaban is increased by all of these drugs as they are strong inhibitors of both CYP3A4 and P-glycoprotein (P-gp). The manufacturer of rivaroxaban has advised that concomitant use should be avoided.
Dabigatran	Amiodarone and verapamil — plasma concentration of dabigatran is increased by amiodarone and verapamil. If concurrent use of dabigatran and amiodarone or verapamil is indicated, reduce the dose of dabigatran to 110 mg twice daily.
	Ciclosporin, dronedarone, itraconazole, ketoconazole, and tacrolimus — the plasma concentration of dabigatran is increased by all of these drugs. The manufacturer of dabigatran has advised that concomitant use should be avoided.
	Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine re-uptake inhibitors (SNRIs) — there is a possible increased risk of bleeding when dabigatran is given with an SSRI or SNRI. The manufacturer of dabigatran advises close clinical monitoring, especially if other risk factors which increase plasma levels are also present.

Page 20 of 41

FINAL (Review: March 2021) Ref - Anticoagulation Policy

0092101

	Swallowing difficulties	Enteral Feeding tubes
Edoxaban	The tablets can be crushed and dispersed in water. Can be mixed with apple puree in patients who are unable to swallow	Can be administered via NG tube. No specific instructions.
Apixaban	The tablets can be crushed and dispersed in water, glucose 5%, apple juice, or apple puree for administration to patients with swallowing difficulties. Take care to ensure the whole dose is administered.	The tablets can be crushed and dispersed in water or in glucose 5% for administration (the manufacturers recommend 60mL). They are licensed for administration through nasogastric tubes - administration through other types of enteral feeding tube would be outside the product license. Take care to ensure the whole dose is administered, and flush well after each dose.
Rivaroxaban	The tablets can be crushed and mixed with water or apple puree immediately prior to administration for patients with swallowing difficulties. Xarelto® tablets are licensed to be administered in this way.	<u>NG/PEG</u> : The tablets can be crushed and mixed with water for administration. Click here for further information. Re-start the feed immediately after the dose has been given and the feeding tube flushed (15mg and 20mg doses). Xarelto® tablets are licensed to be administered in this way. <u>NJ/PEJ/</u> : Rivaroxaban is not suitable for administration via enteral feeding tubes terminating beyond the stomach (i.e. in the duodenum or jejunum) due to decreased absorption of the drug when given in this manner. Bioavailability is significantly reduced when rivaroxaban is administered beyond the stomach.
Dabigatran	tract. The pellets inside the shell are designed to create an acidic mi	ially formulated to release slowly at the correct point in the gastrointestinal cro-environment to improve drug dissolution and absorption. Opening the a risk of increased side effects (i.e. bleeding), therefore this should never be
Warfarin	5mg/5ml oral suspension available. The tablets can be crushed and mixed with water for administration. Without crushing they disperse in two to five minutes.	<u>NG/PEG:</u> Liquid and crushed/dispersed tablets can be administered <u>NJ/PEJ</u> : Warfarin appears to be absorbed high in the GI tract and so there is a risk of reduced absorption if the drug is given through enteral feeding tubes terminating beyond the stomach. When such administration is necessary, monitor the patient closely for effect, and take particular care if the site of delivery is altered (i.e. if the jejunal tube is changed for a gastric one).

Administration to patients with enteral feeding tubes or swallowing difficulties

FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101 Page 21 of 41

6. MANAGEMENT OF OVER ANTICOAGULATION AND REVERSAL OF BLEEDING

Contact Haematology on 585 or via switchboard out-of-hours if patient is haemorrhaging on anticoagulants.

See Clinical guideline – <u>Perioperative management of patients on anticoagulant and</u> <u>antiplatelet agents</u> and the <u>Blood Transfusion Policy</u> for further guidance.

Important considerations:

- Recombinant factor VIIa is not recommended for emergency warfarin reversal.
- Fresh Frozen plasma produces suboptimal anticoagulation reversal and should only be used if prothrombin complex concentrate is not available.
- For surgery that requires reversal of warfarin and that can be delayed for 6 -12 hours, the INR can be corrected using Vitamin K. PCC should not be used for elective or non-urgent surgery.
- For surgery that requires reversal of warfarin which cannot be delayed, INR can be corrected using PCC and Vitamin K.
- For some conditions such as prosthetic heart valves, the degree of reversal must be decided on an individual basis.
- <u>All patients</u> with bleeding should be investigated for underlying cause (particularly in unexpected bleeding at therapeutic levels). A **DATIX** should be completed for patients taking anticoagulation.

<u>Warfarin</u>

Vitamin K exists in both water soluble form (Menadiol) and water insoluble form (Phytomenadione). Phytomenadione is licensed for reversal of anticoagulation. Menadiol is licensed for prevention of Vitamin K deficiency in malabsorption syndromes. Phytomenadione 2mg/0.2ml and 10mg/1ml can be given by both IV injection and orally. Use

of Vitamin K may be followed by a period of warfarin resistance; high thrombosis risk patients may require LMWH (once cessation of bleeding is confirmed).


Management of high INRs (NICE CG144)	
Major bleeding + high INR	Stop warfarin. Seek Haematology Advice.
	See Blood Transfusion Policy for Beriplex
	guidance
INR >8 no bleeding or minor bleeding	Stop Warfarin
	Give Phytomenadione 0.5-1mg slow IV OR 1-
	5mg by mouth (IV Phytomenadione can be
	administered orally). *2mg PO is given to
	non-bleeding outpatients
INR between 6.0 – 8.0 no bleeding or minor	Stop Warfarin
bleeding	Restart when INR <5
INR Less than 6, but more than 0.5units	Reduce dose OR stop warfarin
above the target value	Restart when INR <5
INR Less than 5.0	Reduce dose and/or omit 1-2 doses
	Retest INR in 2-3 days

NOACs

See table below and contact haematology for advice.

FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101 Page 22 of 41

Bedford Hospital



** Hb drop >2.0g/L or bleeding at critical site

Haemodialysis can also be considered. 4 hours of haemodialysis will remove approx. 50- 60% of dabigatran from circulation

NOAC	Half life	Relevant clotting marker
Dabigatran	13 – 18 hour (depending on age/renal impairment)	TT – Iow levels suggest Iow plasma concentration
Rivaroxaban	5 – 13 hours (depending on age/renal impairment)	PT – Iow levels suggest Iow plasma concentration
Edoxaban	10 – 14 hours	As above
Apixaban	12 hours	None

Ret - Anticoagulation Policy 0092101

23 of 41

Praxbind (Idarucizumab) Information

Call Haematology Consultant on-call before use

What is Praxbind?

Praxbind (Idarucizumab) 2.5g/50mL is a specific reversal agent for dabigatran. Idarucizumab (a humanized monoclonal antibody fragment) binds to dabigatran and its metabolites with high affinity and neutralises their anticoagulant effect.

What is Praxbind used for?

Praxbind is indicated in adult patients treated with Pradaxa (dabigatran) when rapid reversal of its anticoagulant effects is required:

- For emergency surgery or urgent procedures
- In life-threatening or uncontrolled bleeding

Dabigatran plasma levels peak within 2–3 hours. In individuals with normal renal function, the half-life is 13 h (plasma half-life 22–35 hours with creatinine clearance < 30 ml/min). For **elective** surgeries/procedures, dabigatran should be stopped 24-48 hours prior to admission.

Location: Praxbind can be obtained from Pharmacy during opening hours or from the Treatment room fridge on AAU out of hours.

What is the recommended dose?

The recommended dose is 5g (2 x 2.5g/50ml vials).

Administration of a second 5g dose may be considered if:

- Recurrence of clinically significant bleeding together with prolonged clotting times OR
- If potential re-bleeding would be life-threatening and prolonged clotting times are observed OR

• Patients require a second emergency surgery/urgent procedure and have prolonged clotting times No dose adjustment is required in renal impairment, hepatic impairment or the elderly.

Coagulation Screening Tests

- - - -

PT, APTT, TT, Fibrinogen and D-dimer should be done **as soon as possible** <u>prior</u> to administration of praxbind (unless a delay in waiting for results has life-threatening consequences).

...

Effect of Dabig	atran on specialist tests of haemostasis
APTT	Curvilinear response to dabigatran, however some patient
	with therapeutic concentrations of dabigatran can still show a
	normal APTT
TT	Linear concentration response. A normal TT suggests the dabigatran level is minimal
PT	Dabigatran has a less marked effect on PT than APTT. Mean PT/INR ratio <1.5
Fibrinogen	No effect on several assays
D-Dimer	Unaffected
FINAL (Review: M	,
Dof Ar	ticongulation Boliov

Ref - Anticoagulation Policy 0092101

How is Praxbind administrated?

Praxbind is for intravenous use only. It does not require reconstitution. It is administered as two consecutive infusions over 5 to 10 minutes each via a syringe driver or as a bolus injection.

Side effects

No adverse effects have been identified. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. www.mhra.gov.uk/yellowcard

How and when do you restart antithrombotic therapy?

Reversing antithrombotic therapy exposes the patient to the thrombotic risk of their underlying condition.

Dabigatran can be restarted 24 hours after administration of Praxbind, if the patient is clinically stable and adequate haemostasis has been achieved.

Other antithrombotic therapy such as low molecular weight heparins can be started any time after the administration of Praxbind, if the patient is clinically stable and adequate haemostasis has been achieved.

Storage

Praxbind is to be stored in a refrigerator (2-8°C).

Prior to use, the unopened vial may be kept at room temperature for up to 48 hours, if stored in the original package in order to protect from light, or up to 6 hours when exposed to light. After opening, chemical and physical in-use stability has been demonstrated for 1 hour at room temperature.

References

Makris, M., Van Veen, J., Tait, C., Mumford, A. and Laffan, M. (2012) 'Guideline on the management of bleeding in patients on antithrombotic agents', British Journal of Haematology, (160), pp. 35 - 46.

Kitchen, S., Gray, E., Mackie, I., Baglin, T., and Makris, M. (2014) 'Measurement of noncoumarin anticoagulants and their effects on tests of Haemostasis', *British Journal of Haematology*, (166), pp. 830 - 841.

SPC Praxbind. Accessed December 2017.www.emc.medicines.org.uk

Use of Prothrombin Complex Concentrate (Beriplex) at Bedford Hospital

Beriplex® P/N is a Prothrombin Complex Concentrate (PCC) containing all four vitamin Kdependent coagulation factors II, VII, IX and X. It also contains small amounts of Antithrombin III, protein C and S.

Beriplex® P/N is issued from the Transfusion lab.

Beriplex® P/N will not be issued unless an accurately completed checklist accompanies the request.

Further guidance relating to the management of bleeding, the use of Beriplex and Fresh Frozen Plasma can be found in the <u>Blood Transfusion Policy</u>.

The Beriplex website (<u>www.beriplex.co.uk/hcp-beriplex</u>) also has prescribing information to assist with dosing and administration.

7. MANAGEMENT OF ENDOSCOPY PATIENTS ON ANTICOAGULATION

Separate guidance is available on the management of endoscopy patients.

The British Society of Gastroenterologists has guidance on <u>the management of patients</u> <u>undergoing elective endoscopic gastro-intestinal procedures</u>. Recommendations are outlined in algorithms in the policy.

The European Society of Gastrointestinal Endoscopy has a policy that discusses the management of anticoagulation in acute non-variceal upper gastro-intestinal haemorrhage.

8. ANTICOAGULATION AND EPIDURAL INFUSIONS

An epidural should not be inserted or removed within 12 hours of a dose of heparin (fractionated or unfractionated). Once the catheter is removed 6 hours must elapse before any further dose of heparin is given.

See Clinical Guideline – <u>Management of epidural infusions (adults)</u> for further guidance.

FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101 Page 26 of 41

9. OTHER VITAMIN K ANTAGONISTS

This section is for information only these drugs are not to be routinely prescribed. Seek advice from haematology if patients are not suitable for warfarin, NOACs or LMWH.

Approximate dosage conversions		
Phenindione dose	Acenocoumarol dose	Warfarin dose
20mg	0.5mg	1mg
35mg	1.0mg	2mg
50mg	1.5mg	3mg
70mg	2.0mg	4mg
80mg	2.5mg	5mg
100mg	3.0mg	6mg
120mg	3.5mg	7mg
135mg	4.0mg	8mg
150mg	4.5mg	9mg
170mg	5.0mg	10mg

10. THROMBOPHILIA AND TESTING

Thrombophilia is an abnormality of blood coagulation associated with hypercoagulability (or prothrombotic state) which increases the risk of thrombosis. Thrombophilia can generally be regarded as either heritable or acquired (see examples below).

Heritable thrombophilia:

- 1. Factor V Leiden
- 2. Prothrombin G20210A
- 3. Protein C deficiency
- 4. Protein S deficiency
- 5. Antithrombin III deficiency
- 6. Dysfibrinogenaemia

Acquired thrombophilias:

- 1. Antiphospholipid Syndrome
- 2. Hyperhomocysteinaemia
- 3. Myeloproliferative disorders
- 4. Paroxysmal nocturnal haemoglobinuria

Patients with protein C deficiency are at risk of developing skin necrosis when starting warfarin treatment. In patients with protein C deficiency, therapy should be introduced without a loading dose of warfarin even if heparin is given. Patients with protein S deficiency may also be at risk and it is advisable to introduce warfarin therapy slowly in these circumstances.

Thrombophilia testing: FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101

- Do not offer thrombophilia testing to patients who are continuing anticoagulation treatment
- Consider testing for antiphospholipid antibodies in patients who have had unprovoked DVT or PE if it is planned to stop anticoagulation treatment, and should be done at least 4 weeks after stopping anticoagulation.
- Consider testing for hereditary thrombophilia in patients who have had unprovoked DVT or PE and who have a first-degree relative who has had DVT or PE if it is planned to stop anticoagulation treatment, and should be done at least 4 weeks after stopping anticoagulation.
- Do not offer thrombophilia testing to patients who have had provoked DVT or PE.
- Do not routinely offer thrombophilia testing to first-degree relatives of people with a history of DVT or PE and thrombophilia.
- Thrombophilia testing rarely alter the patient's management.
- There is no clear evidence base for testing.
- It does not predict the risk of recurrence in unselected VTE patients.
- It is not recommended in arterial clots except for antiphospholipid syndrome.
- It is not indicated in Retinal Vein Occlusion.
- Unknown significance/indication for upper limb thrombosis, cerebral sinus thrombosis, and intraabdominal vein thrombosis.

11. TRAVEL-RELATED VENOUS THROMBOEMBOLISM

Global use of compression stockings and anticoagulation for long distance travel is not indicated. Assessment of risk should be made on an individual basis (see tables below).

Traveller's at the highest risk of travel-related thrombosis undertaking journeys of >3hrs should wear well fitted below-knee compression hosiery. Where pharmacological prevention is considered appropriate, anticoagulants as opposed to anti-platelets are recommended (unless contraindicated).

Duration of travel	<3 hours	3 – 8 hours	>8 hours
Low Risk	Nil	Nil	Nil
Medium Risk	Nil	Nil or Stockings	Stockings
High Risk	Nil	Stockings	Stockings +/-
_			Anticoagulants (e.g.
			warfarin)

	Examples of thrombosis risk factors for VTE
Low Risk	None
Medium Risk	 All others e.g. Up to 6 weeks post-partum Previous unprovoked VTE no longer on anticoagulants Previous travel-related VTE Combinations of risk factors
High Risk	 Major surgery in previous 4 weeks Active cancer undergoing chemo-radiotherapy in the previous 6 months, awaiting surgery or chemo-radiotherapy, or in palliative phase

Please note: patients will be expected to buy these products prior to travel

12. ANTICOAGULATION OUTPATIENT SERVICES IN BEDFORDSHIRE

Oral anticoagulants are generally prescribed on a shared care basis, with treatment initiated in secondary care being continued by GP practices. Safe anticoagulant therapy relies on clear communication between all parties concerned. This applies to all anticoagulation not just warfarin.

Bedfordshire patients on VKA oral anticoagulation therapy are managed by Bedford Warfarin Service, Level 4 GP surgeries or the Anticoagulation Clinic at Bedford Hospital.

Management includes arranging blood sampling for INR and dosing patients based on their results. Prescribing responsibility lies with the clinician/GP.

There are several options for getting a blood sample taken for an INR as an outpatient:

- POC testing in clinic (finger prick)
- Venous sample taken by community phlebotomist who visits the home
- Venous sample taken at outpatient clinic (i.e. Cauldwell Centre)
- Venous sample taken at GP surgery
- Self-testing (patients that do their own finger prick testing at home)

Patients can receive their dosing schedule in their yellow book or via a Postal Dosage Slip (see Appendix 7)

Bedford Warfarin Service

The <u>Bedford Warfarin Service</u> (01234 893413) is part of Bedfordshire Community Health Services and manages stable or largely uncomplicated patients over the age of 18. The service runs from Monday to Friday 8.30am-4pm and offers both clinic and domiciliary appointments. Access into the service is by GP referral and the patient must be registered with a Bedfordshire GP.

Level 4 GP Surgeries

GP surgeries that provide a Level 4 Local Enhanced Service for Anticoagulation monitoring to their warfarin patients. They manage their own stable or largely uncomplicated warfarin patients over the age of 18. Clinic times will vary depending on the surgery and some may offer domiciliary appointments.

Current Level 4 GP Surgeries in Bedfordshire Subject to change			
Surgery	Contact Tel No	Surgery	Contact Tel No
Goldington Road	01234 351341	Queens Park Surgery	01234 213300
De Parys Medical Practice	01234 350022	Templars Way Sharnbrook	01234 781392
Pemberley Surgery	01234 351051	Ivel Medical Centre	01767 312441
Houghton Close Surgery	01525 300898	Station Road, Lower Stondon	01462 850305
Cranfield & Marston	01234 766551	Greensands Surgery Potton	01767 260340
Goldington Avenue	01234 349531	Shefford Healthcare	01462 818620
Great Barford Surgery	01234 870325	Sandy Healthcare	01767 682525
Harrold Medical Practice	01234 720225	Barton-Le-Clay Surgery	01582 528701
Putnoe Medical Practice	01234 319992		

Anticoagulation Clinic Service at Bedford Hospital

The anticoagulant service is currently based in the haematology unit of South Wing, Bedford Hospital.

Opening hours - Monday to Friday 9 - 5pm

Useful contact numbers:

General enquiries – 01234795736 (external), ext. 2207(internal) Anticoagulation specialist nurse/pharmacist – Bleep 467 POD - 18

The target population for this service include:

- Patients who are currently on warfarin therapy in primary care and are 'unstable' in terms of target INR ('stable' is defined as having had INR readings within target range for 3 consecutive readings and considered appropriate for transfer back into GP care)
- Patients newly prescribed anticoagulation therapy
- Complex high risk patients such as:
 - Patients with alcohol dependence prone to instability in anticoagulation management
 - Patients with a known hereditary or acquired bleeding disorder
 - Patients with severe malnourishment due to absorption difficulties
 - Mentally ill with no carer support in the community
 - o Dementia with no carer support in the community
 - Patients with liver failure
 - o Patients with severe renal impairment
 - Patients with documented evidence of CNS haemorrhage
 - Patients with severe heart failure
 - Patients with uncontrolled hypertension
 - Patients with gastrointestinal bleeding within the last 6 months
 - Pregnant women (urgent referral to Haematologist Consultant)
 - o Patients receiving chemotherapy for malignant tumours
 - Children under 16 years (this service is not provided under the outpatient service)
 - Homozygous protein C deficiency (risk of skin necrosis)

For management of outpatients in the following scenarios please see local anticoagulation clinic policies/SOPs.

- Dosing warfarin patients whilst they are abroad
- Patients self-testing INRs on Coagucheck
- Managing patients who DNA clinic appointments
- Dealing with High INRs Out of hours (Outpatients only)
- Anticoagulant clinic advice for patients leaflet and postal advice leaflets.

Responsibilities of Secondary Care

- Initiate, monitor and titrate anticoagulation treatment for appropriate patients referred into the service.
- Review and confirm patient education regarding anticoagulant therapy
- Provide urgent medical advice relating to anticoagulation.
- Accept patients who are maybe not suitable for anticoagulation monitoring in primary care (refer to Target Population)
- Ensure transfer of care from secondary to primary care is seamless in terms of patients' anticoagulant therapy.
- Provide INR testing from venous samples or POC testing (finger prick testing).
- Patients internally referred to the Anticoagulation Clinic must be risk assessed for risk of bleed by referring consultant/physician. A signed and completed 'Anticoagulation Referral Form' and signed prescription needs to also be completed.
- Referring consultant/physician assumes full overarching clinical responsibility in the care and management of the patient

Responsibilities of Bedfordshire CCG

The role of Bedfordshire CCG is to ensure that services provided in primary care are in accordance with the service level agreement for the provision of level 4 anticoagulation services including the following:

- Ensuring the NPSA safety alert 18 (Action that can make anticoagulant therapy safer) March 2007 is implement in GP Practices
- Develop, update and review the Local Enhanced Service for Anticoagulation in Primary Care as necessary
- Ensure Anticoagulation Therapy Guidelines, training packs and Standard Operating Procedures to support GP Practices are implemented by Level 5 anticoagulation practices.
- Ensure anticoagulation guidelines are available for the management of under and over anticoagulation
- Ensuring regular clinical audit is undertaken.
- Ensure that adequate capacity exists in primary care for the smooth transfer of stable patients (thee INRs in target range) back into the care of their GP.

Responsibilities of Level 4 GP Practices and other Bedfordshire Anticoagulation Service Providers

To develop practice Standard Operating Procedures or detailed anticoagulation policies, which are read and signed by all relevant staff and responsibilities of staff are clear and understood.

- Ensuring appropriate training is undertaken by all staff involved in anticoagulation and evidence of this training is documented. All competencies must be satisfactory before undertaking the service.
- Training on Computerised Decision Support Software (CDSS) is completed prior to implementation, if used.
- The appropriate equipment for testing INR and vitamin K is available at the anticoagulation clinic/ GP surgery.
- Training on POC testing meters must be undertaken before testing can commence.
- Ensuring internal and external audit for the equipment used in anticoagulation is undertaken and results submitted as required.
- Perform and record clinical audit including development of action plans and re-audit.
- Ensure a GP is available at all times when anticoagulation services are offered to patients by the practice.
- Ensure reception staff are aware of the importance of patients attending within a specified period so that appointments are not delayed without guidance from appropriate clinical staff.

FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101

- Ensure transfer of care from secondary to primary care is seamless in terms of patients' anticoagulant therapy.
- Appropriate reversal medications are stored on site to deal with the management of urgent cases, such as reversal of high INR levels with Vitamin K formulations. Konakion MM paediatric is available as 2mg/0.2ml ampoules and can be given orally which licensed for oral administration

Responsibilities of Patient's GP

Overall responsibility for the care of the patients continues to reside with the registered GP who may be required to provide prescriptions for anticoagulation therapy and includes:

- Ensuring that dose recommendations and recall are guided by approved written protocols or Computerised Decision Support Software (CDSS).
- Ensuring patients receive education regarding anticoagulant therapy.
- Giving advice on duration and intensity of anticoagulation as guided by initiating clinician.
- Being aware of the potential effects of additional therapy given to a patient on anticoagulants, and arranging earlier INR testing as required.
- Acting promptly to patients with bleeding problems and/or INR > 8 or who are otherwise considered to be at risk of bleeding.
- Dosing decisions should be made by health-care professionals (e.g. GP's, registered pharmacists or registered nurses) who have undergone an approved course for practitioners undertaking anticoagulant monitoring in primary care and who are deemed competent under relevant competency frameworks.
- Arranging admission to hospital if required.
- Issuing warfarin prescriptions.
- Appropriate reversal medications are stored on site and arrangements exist with Out of Hours Services (Herts Urgent Care) to deal with the management of urgent cases, such as reversal of high INR levels with Vitamin K formulations. Konakion MM paediatric is available as 2mg/0.2ml ampoules and can be administered orally is licensed for oral administration.
- Ensuring that all patients receive appropriate monitoring, either with primary care anticoagulation service or in secondary care.
- To stop the anticoagulant when specified duration is complete, this decision can also be made by secondary care where it has been initiated by the hospital
- On initiation of therapy the patient is assessed on their ability to take warfarin safely (risk assessment of patients for oral anticoagulation)
- Ensuring that patients, who do not speak, read or write English or who have communication difficulties (including without limitation hearing, oral or learning impairments) are provided with appropriate assistance. A responsible person or carer should be identified who can assist patient with any dose alterations.

13. BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE ADVICE

Open link to see local advice and guidance on anticoagulants from Bedfordshire CCG.

http://www.gpref.bedfordshire.nhs.uk/referrals/bedfordshire-and-luton-joint-prescribingcommittee-(jpc)/jpc-advice-and-guidance.aspx

14. AUDIT

Every 2 years the parameters from the <u>NPSA audit checklist</u> will be audited prospectively by the Anticoagulation Outpatient Clinic at Bedford Hospital using the information on referral forms and DAWN (the Computerised Decision Support System).

Audits will be reported back to the Haemostasis and Thrombosis Committee/Drugs and Therapeutics Committee.

Patient safety incident data involving anticoagulants will be documented through the trust Datix system and reviewed by the Medicines Safety Committee. Root Cause analysis investigation report will be completed for Serious Incidents and reviewed by the Haemostasis and Thrombosis Committee.

15. EDUCATION AND TRAINING Prescribers

All prescribers that initiate, continue or adjust dosage of anticoagulants must be competent to undertake their work safely. Any gaps in competence must be addressed through training to ensure that staff may undertake their duties safely.

The Foundation doctors' induction includes a presentation on Anticoagulation therapy. Medical prescribers are also assessed on anticoagulation as part of the National Prescribing Skills assessment and the Competency Testing for Bedford Prescribers.

All prescribers are advised to complete the BMJ E-Learning packages: <u>Starting patients on anticoagulants in secondary care: how to do it</u> <u>Maintaining patients on oral anticoagulants: how to do it</u>

Nursing Staff

Nursing staff (including PRPs) who are authorised to administer medications under the 'Administration of Medicines Policy (MP4)' may administer anticoagulants. Nurses who are required to prepare or administer heparin therapy must have completed the Intravenous administration competency outlined in the Administration of Medicines Policy.

It is the responsibility of line managers to ensure staff that administer or discharge patients on anticoagulants have sufficient knowledge to fulfil their responsibilities under this policy.

Pharmacy Staff

Pharmacists involved in clinically screening prescriptions for anticoagulants are advised to complete the CPPE E-Learning package Anticoagulation: initiation, management, patient support and safety.

Medicines Management technicians and ward based pharmacy technicians must have sufficient knowledge of anticoagulants to provide appropriate counselling to patients when required.

16. RESPONSIBILITIES

Haemostasis and Thrombosis Committee

It is the responsibility of the Haemostasis and Thrombosis Committee to ensure that the Trust protocols are evidence based, in line with National Guidance and up to date.

Prescribers

<u>General responsibilities</u> FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101 Senior Clinicians are responsible for ensuring that all staff, particularly junior doctors, pre-op assessment staff and non-medical prescribers, keep up to date and implement the trust policy and clinical protocols. Junior doctors are responsible for implementing the protocols for all patients - as inpatients and on discharge.

Inpatient prescribing

For inpatients, VKAs should be prescribed on the 'Variable dose' tab on MedChart, unfractionated heparin on the IV Fluid Chart and other oral anticoagulants and LMWH on the Scheduled tab on MedChart.

In areas that do not use MedChart or during extended system downtime, VKAs will be prescribed on the anticoagulant paper charts which can be found in the offline charts cupboard.

The daily dose must be prescribed before 5pm wherever possible.

Dosing should not be left for the out-of-hours cover team to complete.

Prescribing on discharge

On discharge, all anticoagulants should be prescribed on the TTO. Dosing information for VKAs will be written in a Yellow book. See Appendix 9 for further information regarding referrals.

Monitoring

INR must be checked within 1-2 days of any change in other medication. Any significant change in clinical presentation in a patient on warfarin should trigger an immediate INR test and repeat INRs may be necessary whilst the patient remains unwell. Where patients on NOACs have a significant change in clinical presentation bleeding should be considered and an immediate haemoglobin check carried out. A change in renal function can also result in accumulation of active drug and NOACs and LMWHs may need to be dose reduced or withheld until renal function recovers.

Nursing Staff

Administration

VKAs should be administered on the 5-6pm drug administration round. If the dose is not prescribed by mid-afternoon the clinical team should be contacted to prescribe the dose as soon as possible.

Before administering parenteral, subcutaneous or oral anticoagulants to a patient the nurse should carry out all checks as per MP4: Administration of Medicines Policy including recent INR for VKAs.

After administering anticoagulation to a patient, the nurse should:

- Monitor for any signs of bleeding
- Manage the patients' risk of falls on the ward

Discharge

The nurse must ensure the discharge checklists in Appendix 8 have been completed.

The nurse issuing the discharge medication to the patient must check that the current anticoagulant dose (and when this dose is due to be taken) has been communicated to the patient or carer. The nurse should also confirm that the patient has understood this information. For VKA patients, the yellow book must be sent with them at discharge.

FINAL (Review: March 2021) Ref - Anticoagulation Policy 0092101 A patient requiring LMWH on discharge should be counselled on how to administer. If the patient/carer is unable to self-administer, the ward nurse should make arrangements with the appropriate community team.

Discharge checklists should be filed in the patients' medical notes once complete.

Pharmacy Staff

Medicines reconciliation

Ensure the maintenance dose of warfarin is recorded on medicines on admission. Establish which clinic the patient is under and inform them of the patients' admission to hospital.

Clinical screening of inpatient prescriptions

- Pharmacists should clinically screen all prescriptions for anticoagulants to confirm that the drug, dose and route are appropriate for the patient and therapy is safe and cost effective. Any problems including significant drug interactions should be discussed with the prescriber and appropriate action taken.
- Pharmacists should check that a recent, satisfactory INR test has been performed and recorded before approving a VKA prescription

Dispensing

- Patients should be provided with the minimum number of strengths of warfarin requires for them to take the prescribed dose. This will normally be 1mg and 3mg tablets but could include 500microgram and 5mg tablets if necessary. Tablets of 500micrograms may be required to prevent patients from halving tablets which can lead to inaccuracies in dosage.
- Dispensing labels for VKAs should state "Take as directed on your anticoagulant card" and should not include a specific dose.
- NPSA OAT packs and Yellow books are supplied from pharmacy and will be held as ward stock in all areas where they are commonly required. Ward stock supplies will be reordered or topped-up in the same way as stock drugs supplied from pharmacy.

Discharge

As part of the clinical screening process for TTOs, pharmacists must ensure the prescriber has completed the necessary referral forms.

The NOAC initiation checklist should be completed by either the nursing staff or pharmacy staff and filed in the patients' medical notes once complete.

References	BCSH Guidelines (2007): Safety indicators for inpatient and
Kelerences	outpatient oral anticoagulant care; British Journal Haematology; 136, 26-29.
	Heneghan et al (2010) Optimal loading dose for the initiation of warfarin: a systematic review. BMC Cardiovascular Disorders, 10:18.
	Bhavnani M & Shwe K. (1998) A warfarin induction regimen for outpatient anticoagulation in patients with atrial fibrillation. British Journal of Haematology,102:1110
	British National Formulary (BNF) August 2018 Update. Accessed via: https://about.medicinescomplete.com/
	European Society of Cardiology (ESC). (2010) Guidelines for the management of atrial fibrillation. European Heart Journal; 31, 2369-2429
	European Society of Cardiology (ESC). (2012) An update of the 2010 ESC Guidelines for the management of atrial fibrillation. European Heart Journal: August; 33, 2719-2747
	Fennerty et al.(1998) British Medical Journal;297;1285-8
	Hart R. G., Pearce L. A., Aguilar M. I. (2007) Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med. 146: 857-867
	Keeling et al, (2011) Guidelines on oral anticoagulation with warfarin – fourth edition. British Journal of Haematology; 154, 311-324
	Linkins, L.A., Choi, P.T. & Douketis, J.D. (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med, 139, 893-900.
	Lip G. Y., Frison L., Halperin J., Lane D. (2010) Identifying patients at risk of stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. Oct; 41: 2731-2738
	Makris et al (2012) Guideline on the management of bleeding in patients on antithrombotic agents, British Journal of Haematology; 160, 35-46
	NICE Clinical Guideline 144: Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, November 2015.
	National Patient Safety Agency (NPSA) Alert no. 18:

	Actions that can make anticoagulant therapy safer, March 2007. Oden, A. & Fahlen, M. (2002) Oral anticoagulation and risk of death: a medical record linkage study. BMJ; 325:1073-1075.
	Petersen P, Boysen G, Godtfredsen J, et al. (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet.1:175–179.
Staff involved in development	Muhsin Almusawy - Consultant Haematologist Deena Bengtson - Lead Pharmacist Haemostasis and Thrombosis

Approving Signatories

Name of Leading Sub-Committee / Business Ur Approving this Guideline:

Name of Leading Sub-Committee / Business Unit Haemostasis and Thrombosis Committee

Date: 4/4/2019	Date:
Signature: Muhsin Abrandow J	Signature:
Print Name: MUHSIN ALMUSAWY	Print Name:
(Chairperson of Board or Committee Indicated above)	(Chalrperson of Board or Committee indicated above)

Name of Other Sub-Committee / Business Unit involved in Approval of Guideline:

Drugs and Therapeutics Committee

Date: 10/4/9	Date:
Signature:	Signature:
Print Name:	Print Name:
(Chairperson of Board or Committee indica above)	itedrescon (Chairperson of Board or Committee indicated above)

Ratification Signature Approved by Quality Board

Date:	
Signature:	
Print Name	

Consultation List A completed list should accompany every guideline/policy (This gives evidence on who has seen this Guideline and any comments made)		Bedford Hospital NHS Trust
Name of Person	Department or Committee	Comments
Aoife McKnight	Lead Nurse Planned care	No comment
Arindam Chaudhuri	Consultant Vascular Surgeon	No comment
Cathy Pullen	Lead Nurse Integrated Medicine	No comment
Helen Friend	Associate Director of Quality Improvement	No comment
John Cooper	Consultant Cardiologist	No comment
Lia Contino	VTE coordinator	No comment
Matthew Lock	Principal Pharmacist for Integrated Medicine	Comments incorporated
Oilin Man	Lead Pharmacist Admissions	No comment
Pallab Rudra	Consultant Anaesthetist	No comment
Paul Tisi	Medical Director	Comments incorporated
Petia Jamalidini	Anticoagulation Specialist Nurse	Comments incorporated
Saba Khan	Clinical Fellow Haematology Doctor	No comment
Sandra Oquaye	Anticoagulation Specialist Nurse	Comments incorporated
Sarah Reynolds	Consultant Obstetrician	No comment
Thomas Larsen	Consultant Emergency Medicine	No comment
Anne Day	Consultant Gastroenterologist	No comment
Alison Melvin	Consultant Endocrinologist	No comment
Awais Bokhari	Consultant Cardiologist	No comment
David Niblett	Clinical Lead Critical Care	Comments incorporated
Max Wilde	General and Colorectal Surgeon	No comment
Jane Daniel	Lead Nurse Integrated Medicine	No comment
Enson C Thomas	Consultant Chest Physician	No comment
Jacquelyn Harvey	Consultant Gastroenterologist	Comments incorporated
Fatima Sogiawalla	Consultant – Ambulatory Care	No comment
Raafat Farag	Consultant Stroke Physician	No comment

Page 40 of 41

John McNamara	Consultant Anaesthetist	No comment
Imad Kamal	Consultant Care of the Older Persons	No comment
Stuart Lloyd	Consultant Emergency Medicine	No comment
Syed Rabbani	Consultant Haematologist	No comment
Julia Callaghan	Deputy Chief Pharmacist (Operations)	No comment
Mohammed Azher	Clinical Director Integrated Medicine/Consultant Respiratory	No comment
Nadim Noor	Consultant Vascular Surgeon	No comment
Elizabeth Curtis	Principal Pharmacist – Planned Care	Comments incorporated
Paul Raynor	Associate Director of Nursing	No comment
Rajeev Kumar	AAU Consultant	No comment
Marlyse Dieuguie-Djontu	AAU Consultant	No comment
Rory Harvey	Consultant Gastroenterologist	No comment
Jeremy Sizer	Clinical Director Planned Care Group	No comment
Sarah Snape	Consultant Anaesthetist	No comment
Sarah Smith	Consultant Oncologist	No comment
Sunilkumar Krishnankutty	AAU Consultant	No comment
Tapan Mehta	Consultant Vascular Surgeon	No comment
William Trounson	Consultant – Care of the Older Persons	No comment
Dan Arvinte	Consultant Trauma & Orthopaedics	No comment
Shane Morrison-McCabe	Divisional Director Integrated Medicine	No comment
Sue Chirico	Specialist Service Manager - Haematology	No comment
Matthew Davies	Locality Pharmaceutical Lead BCCG	No comment
Ruth Patrickson	Bedford Warfarin Clinic Anticoagulation Nurse	No comment
Aidan Vaughan	Deputy Director for Clinical Governance	Comments incorporated relating to policy layout
Drugs and Therapeutics Committee		Comments incorporated
Haemostasis and Thrombosis Committee		Comments incorporated